Biochem/physiol Actions
Target IC50: 0.071, 2.08 & 3.17 µ
Reversible: yes
Primary TargetSHP2
Cell permeable: yes
General description
A cell-permeable, bioavailable, non-toxic p-nitro analog of PHPS1 (Cat. No. 540213) that exhibits enhanced potency and selectivity. Acts as a phosphotyrosine mimetic, substrate-competitive and reversible catalytic domain inhibitor of SHP2 (IC50 = 0.071, 2.08 & 3.17 µM for SHP2, SHP1 & PTP1B, respectively). Dose-dependently reverts HGF-stimulatd epithelial-mesenchymal transition of HPAF II cells and blocks human lung adenocarcinoma LXFA 526L anchorage-independent growth. Shown to significantly retard LXFA 526L xenografted tumor growth in mice (46 mg/kg/day, i.p., q.d.).
A cell-permeable, bioavailable, non-toxic p-nitro analog of PHPS1 (Cat. No. 540213) that exhibits enhanced potency and selectivity. Acts as a phosphotyrosine mimetic, substrate-competitive and reversible catalytic domain inhibitor of SHP2 (IC50 = 0.071, 2.08 & 3.17 µM for SHP2, SHP1 & PTP1B, respectively). Dose-dependently reverts HGF-stimulatd epithelial-mesenchymal transition of HPAF II cells and blocks human lung adenocarcinoma LXFA 526L anchorage-independent growth. Shown to significantly retard LXFA 526L xenografted tumor growth in mice (46 mg/kg/day, i.p., q.d.).Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Grosskopf, S., et al. 2015. ChemMedChem.10, 815.
Packaging
Packaged under inert gas
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria to qualify for the following awards: